Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2016

Prior Authorization Required for Taltz

Effective immediately, Harvard Pilgrim is now covering the medication Taltz with prior authorization. In March, the U.S. Food and Drug Administration approved Taltz, which is administered by injection, for the treatment of moderate-to-severe plaque psoriasis in adults. Taltz is covered on the Premium formularies only, at the highest tier (i.e. Tier 3 on the 3-Tier and Tier 4 on the 4-Tier Premium formularies). The drug has a quantity limit of four syringes per 28-day supply.

Harvard Pilgrim is requiring prior authorization to ensure the cost-effective and appropriate use of Taltz. Harvard Pilgrim’s Taltz Clinical Review Criteria detail the requirements that must be met in order to obtain prior authorization. To request prior authorization, please complete the Taltz Medication Request Form and fax it to MedImpact Healthcare Systems at 888-807-6643. For more information, refer to the Pharmacy section of Harvard Pilgrim’s provider website.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Coverage of Narcan Nasal Spray and Evzio

Vraylar: New Clinical Requirements for Coverage

Prior Authorization Required for Taltz

New Medical Policy on Treatment of Benign Prostatic Hypertrophy

Identifying and Treating Obsessive-Compulsive Disorder


Home Care Seasonal Flu Vaccine Fee Schedule Updated for 2016

Reminder: Keep Panel Status Up to Date


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator